130 related articles for article (PubMed ID: 23813420)
1. Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK.
Keenan TD; Kelly SP; Sallam A; Mohamed Q; Tufail A; Johnston RL
Br J Ophthalmol; 2013 Sep; 97(9):1168-72. PubMed ID: 23813420
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom.
Buckle M; Lee A; Mohamed Q; Fletcher E; Sallam A; Healy R; Stratton I; Tufail A; Johnston RL
Eye (Lond); 2015 Mar; 29(3):403-8. PubMed ID: 25592123
[TBL] [Abstract][Full Text] [Related]
3. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes.
Zarranz-Ventura J; Liew G; Johnston RL; Xing W; Akerele T; McKibbin M; Downey L; Natha S; Chakravarthy U; Bailey C; Khan R; Antcliff R; Armstrong S; Varma A; Kumar V; Tsaloumas M; Mandal K; Bunce C; Tufail A;
Ophthalmology; 2014 Oct; 121(10):1966-75. PubMed ID: 24953791
[TBL] [Abstract][Full Text] [Related]
4. UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: Incidence of Blindness and Sight Impairment in Ranibizumab-Treated Patients.
Johnston RL; Lee AY; Buckle M; Antcliff R; Bailey C; McKibbin M; Chakravarthy U; Tufail A;
Ophthalmology; 2016 Nov; 123(11):2386-2392. PubMed ID: 27615601
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK.
Buckle M; Donachie PH; Johnston RL
Br J Ophthalmol; 2016 Feb; 100(2):240-5. PubMed ID: 26124462
[TBL] [Abstract][Full Text] [Related]
7. Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months.
Invernizzi A; Teo K; Nguyen V; Daniell M; Squirrell D; Barthelmes D; Gillies MC
Br J Ophthalmol; 2019 Sep; 103(9):1337-1341. PubMed ID: 30504490
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project.
Daien V; Nguyen V; Morlet N; Arnold JJ; Essex RW; Young S; Hunyor A; Gillies MC; Barthelmes D;
Am J Ophthalmol; 2018 Jun; 190():50-57. PubMed ID: 29550186
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
Pedersen KB; Sjølie AK; Møller F
Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
[TBL] [Abstract][Full Text] [Related]
10. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.
Arnold JJ; Campain A; Barthelmes D; Simpson JM; Guymer RH; Hunyor AP; McAllister IL; Essex RW; Morlet N; Gillies MC;
Ophthalmology; 2015 Jun; 122(6):1212-9. PubMed ID: 25846847
[TBL] [Abstract][Full Text] [Related]
11. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
Algvere PV; Steén B; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
[TBL] [Abstract][Full Text] [Related]
12. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
Lee H; Ji B; Chung H; Kim HC
Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
[TBL] [Abstract][Full Text] [Related]
13. Macula service evaluation and assessing priorities for anti-VEGF treatment in the light of COVID-19.
Stone LG; Devenport A; Stratton IM; Talks JS
Graefes Arch Clin Exp Ophthalmol; 2020 Dec; 258(12):2639-2645. PubMed ID: 32712708
[TBL] [Abstract][Full Text] [Related]
14. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
15. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials.
Barbazetto IA; Saroj N; Shapiro H; Wong P; Ho AC; Freund KB
Am J Ophthalmol; 2010 Jun; 149(6):939-946.e1. PubMed ID: 20378094
[TBL] [Abstract][Full Text] [Related]
16. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study.
Bashshur ZF; Haddad ZA; Schakal AR; Jaafar RF; Saad A; Noureddin BN
Am J Ophthalmol; 2009 Jul; 148(1):59-65.e1. PubMed ID: 19375689
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration associated with poor initial visual acuity.
Galbinur T; Averbukh E; Banin E; Hemo I; Chowers I
Br J Ophthalmol; 2009 Oct; 93(10):1351-2. PubMed ID: 19520693
[TBL] [Abstract][Full Text] [Related]
19. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.
Singer MA; Awh CC; Sadda S; Freeman WR; Antoszyk AN; Wong P; Tuomi L
Ophthalmology; 2012 Jun; 119(6):1175-83. PubMed ID: 22306121
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
Kaiser PK; Brown DM; Zhang K; Hudson HL; Holz FG; Shapiro H; Schneider S; Acharya NR
Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
